With Artificial Intelligence (AI) being the talk of town, It’s not just for techies anymore. By 2021, the AI healthcare market value hit $6.6 billion.

Limits of Traditional Tools

For years, diagnosing cancer has relied on the keen eyes of pathologists. They examine tissue samples under microscopes, looking for signs of disease. This process, while critical, is time-consuming, highly specialized, and subject to human error. As cancer cases rise, the demand on pathology services has never been higher. 

Tech to the Rescue

AI and machine learning offer speed, accuracy, and efficiency far beyond traditional methods. AI doesn’t tire or get overwhelmed by volume. It can analyze thousands of cases, learning and improving with each one. Research has shown AI can match or even surpass human accuracy in identifying cancerous cells.

Two Visionaries Unite

Aneesh Sathe and Kaveh Taghipour are the brains behind Qritive. Both founders come from strong academic backgrounds, honed at the National University of Singapore (NUS). Aneesh, holding a PhD in Mechanobiology, created computer vision systems to spot cancer cells. Kaveh, with a PhD in Natural Language Processing, developed systems for extracting information and text classification. 

Their expertise in imaging and data analysis, became Qritive’s foundation​. The journey began when Aneesh and Kaveh realized the untapped potential of computational tools in pathology. 

With 70% of pathologists concentrated in just 10 countries, nearly half the global population lacked basic diagnostic access. This disparity in healthcare services, coupled with the increasing complexity of diagnostics, urged them to act.

What Does Qritive Do?

Qritive makes cancer diagnosis faster, cheaper, and more accurate. How? By merging AI with pathology. Their innovative tools are designed to analyze both microscopic images and electronic medical records, offering potential diagnoses that aim to elevate the standards of patient care.

Qritive’s portfolio includes Pantheon TM and QAi Prostate, among others. These tools are designed to support pathologists providing critical insights needed for diagnosing cancer. 

Qritive’s technology is not just limited to diagnosis. They offer a complete ecosystem for pathology. This includes preparing whole slide imaging and using deep learning techniques.

Qritive’s Game-Changing Products

Pantheon TM

Pantheon TM is the flagship product of Qritive. This AI-driven ecosystem is transforming pathology by digitizing the entire workflow. From case management to AI analysis of whole-slide images. It helps pathologists examine slides digitally.

QAi Prostate

QAi Prostate is a targeted solution for prostate cancer. This AI module accurately identifies prostate cancer from biopsy slides. It employs deep neural networks to grade cancer, significantly reducing manual measurement errors and enhancing diagnostic precision. 

Other AI Modules

Qritive’s suite of AI modules extends to lymphadenopathy, breast, colon cancer, and more. Each module is designed to improve diagnostic confidence by analyzing immunohistochemistry and grading diseases accurately, streamlining pathologists’ work and optimizing patient outcomes.

Pantheon Academy

It’s where Qritive shares its knowledge. Pathologists and scientists learn about AI in pathology here.

The Tech That Makes It Happen

Whole Slide Imaging (WSI) is the foundation of Qritive. WSI involves scanning or digitizing entire glass slides containing tissue specimens into high-resolution digital images. Qritive uses over 400,000 patient samples. This vast data pool trains its algorithms, making them incredibly accurate.

 They’re designed to mimic and enhance the expert eye. These algorithms can spot what humans might miss. Deep learning digs into data, finding patterns no human eye could catch. Pathologists train Qritive’s algorithms. This blend of human expertise and AI precision creates a powerful diagnostic tool. 

What is Whole Slide Imaging?

The core of WSI technology is the scanner, equipped with high-quality optics, precise mechanical movements, and cameras capable of capturing images at different magnifications. 

Scanners convert the physical slides into digital images by taking multiple high-resolution pictures of different sections of the slide and stitching them together seamlessly. This process captures every detail of the slide, allowing pathologists to zoom, scan, and analyze with a click.

Recognition And Partnerships

The implementation of Qritive’s technology in pathology practices has led to clinical studies showing up to 90% faster diagnoses and 80% less discordance. Achieving Class C IVD certification from Singapore’s Health Sciences Authority (HSA) is a testament to Qritive’s high standards. Class C devices are recognized for their demanding rigorous review and quality assurance.

Qritive’s AI has also integrated with Corista’s advanced digital image management. Looking forward, they plan to rope in 4,000 pathologists into their network. They also have partnered with Metropolis Healthcare, Rajiv Gandhi Cancer Institute, and CŌRE Diagnostics in India to bolster AI adoption in pathology workflows.

Financial Milestones

Qritive started its journey with a kickstart from an accelerator program, bagging $56.2K. As it began showing promise, early stage VCs saw potential, injecting another $600K into the startup. The big leap came on January 9, 2023. Qritive secured a whopping $7.5M in a Series A funding round. This round was led by heavyweights such as MassMutual Ventures, SEEDS Capital, and Exfinity Venture Partners.

A Future Shaped by AI

Cancer diagnosis could be lightning-fast and pinpoint accurate. This is what Qritive is building. Let’s watch where Qritive goes next. Dive deeper. Ask questions. Seek answers. Whether you’re a future entrepreneur, a healthcare professional, or simply someone fascinated by this new era in technology, your curiosity can lead to the next big breakthrough.